SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1

James W. Peacock, Ario Takeuchi, Norihiro Hayashi, Liangliang Liu, Kevin J. Tam, Nader Al Nakouzi, Nastaran Khazamipour, Tabitha Tombe, Takashi Dejima, Kevin C.K. Lee, Masaki Shiota, Daksh Thaper, Wilson C.W. Lee, Daniel H.F. Hui, Hidetoshi Kuruma, Larissa Ivanova, Parvin Yenki, Ivy Z.F. Jiao, Shahram Khosravi, Alice L.F. MuiLadan Fazli, Amina Zoubeidi, Mads Daugaard, Martin E. Gleave, Christopher J. Ong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo. SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.

Original languageEnglish
Pages (from-to)219-238
Number of pages20
JournalEMBO Molecular Medicine
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Castration
Receptor Protein-Tyrosine Kinases
Prostatic Neoplasms
Growth
Neoplasms
Ligands
Growth Factor Receptors
Androgen Receptors
Heterografts
Protein-Tyrosine Kinases
plexin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine

Cite this

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. / Peacock, James W.; Takeuchi, Ario; Hayashi, Norihiro; Liu, Liangliang; Tam, Kevin J.; Al Nakouzi, Nader; Khazamipour, Nastaran; Tombe, Tabitha; Dejima, Takashi; Lee, Kevin C.K.; Shiota, Masaki; Thaper, Daksh; Lee, Wilson C.W.; Hui, Daniel H.F.; Kuruma, Hidetoshi; Ivanova, Larissa; Yenki, Parvin; Jiao, Ivy Z.F.; Khosravi, Shahram; Mui, Alice L.F.; Fazli, Ladan; Zoubeidi, Amina; Daugaard, Mads; Gleave, Martin E.; Ong, Christopher J.

In: EMBO Molecular Medicine, Vol. 10, No. 2, 01.02.2018, p. 219-238.

Research output: Contribution to journalArticle

Peacock, JW, Takeuchi, A, Hayashi, N, Liu, L, Tam, KJ, Al Nakouzi, N, Khazamipour, N, Tombe, T, Dejima, T, Lee, KCK, Shiota, M, Thaper, D, Lee, WCW, Hui, DHF, Kuruma, H, Ivanova, L, Yenki, P, Jiao, IZF, Khosravi, S, Mui, ALF, Fazli, L, Zoubeidi, A, Daugaard, M, Gleave, ME & Ong, CJ 2018, 'SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1', EMBO Molecular Medicine, vol. 10, no. 2, pp. 219-238. https://doi.org/10.15252/emmm.201707689
Peacock, James W. ; Takeuchi, Ario ; Hayashi, Norihiro ; Liu, Liangliang ; Tam, Kevin J. ; Al Nakouzi, Nader ; Khazamipour, Nastaran ; Tombe, Tabitha ; Dejima, Takashi ; Lee, Kevin C.K. ; Shiota, Masaki ; Thaper, Daksh ; Lee, Wilson C.W. ; Hui, Daniel H.F. ; Kuruma, Hidetoshi ; Ivanova, Larissa ; Yenki, Parvin ; Jiao, Ivy Z.F. ; Khosravi, Shahram ; Mui, Alice L.F. ; Fazli, Ladan ; Zoubeidi, Amina ; Daugaard, Mads ; Gleave, Martin E. ; Ong, Christopher J. / SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. In: EMBO Molecular Medicine. 2018 ; Vol. 10, No. 2. pp. 219-238.
@article{2da800dfc3ad4351b45ea3a93eb96be8,
title = "SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1",
abstract = "Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo. SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.",
author = "Peacock, {James W.} and Ario Takeuchi and Norihiro Hayashi and Liangliang Liu and Tam, {Kevin J.} and {Al Nakouzi}, Nader and Nastaran Khazamipour and Tabitha Tombe and Takashi Dejima and Lee, {Kevin C.K.} and Masaki Shiota and Daksh Thaper and Lee, {Wilson C.W.} and Hui, {Daniel H.F.} and Hidetoshi Kuruma and Larissa Ivanova and Parvin Yenki and Jiao, {Ivy Z.F.} and Shahram Khosravi and Mui, {Alice L.F.} and Ladan Fazli and Amina Zoubeidi and Mads Daugaard and Gleave, {Martin E.} and Ong, {Christopher J.}",
year = "2018",
month = "2",
day = "1",
doi = "10.15252/emmm.201707689",
language = "English",
volume = "10",
pages = "219--238",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1

AU - Peacock, James W.

AU - Takeuchi, Ario

AU - Hayashi, Norihiro

AU - Liu, Liangliang

AU - Tam, Kevin J.

AU - Al Nakouzi, Nader

AU - Khazamipour, Nastaran

AU - Tombe, Tabitha

AU - Dejima, Takashi

AU - Lee, Kevin C.K.

AU - Shiota, Masaki

AU - Thaper, Daksh

AU - Lee, Wilson C.W.

AU - Hui, Daniel H.F.

AU - Kuruma, Hidetoshi

AU - Ivanova, Larissa

AU - Yenki, Parvin

AU - Jiao, Ivy Z.F.

AU - Khosravi, Shahram

AU - Mui, Alice L.F.

AU - Fazli, Ladan

AU - Zoubeidi, Amina

AU - Daugaard, Mads

AU - Gleave, Martin E.

AU - Ong, Christopher J.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo. SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.

AB - Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo. SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85040736628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040736628&partnerID=8YFLogxK

U2 - 10.15252/emmm.201707689

DO - 10.15252/emmm.201707689

M3 - Article

C2 - 29348142

AN - SCOPUS:85040736628

VL - 10

SP - 219

EP - 238

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 2

ER -